Impact of JAK2V617F Mutational Status on Phenotypic Features in XXXX and Primary @entity4018 .

@entity1 @entity6582 @entity5 @entity49 @entity4016 @entity4018 @entity381 @entity1031 @entity4407 @entity715
OBJECTIVE: The JAK2V617F mutation is present in the majority of @entity1 with @entity4407 ( @entity4407 ) and @entity4018 ( @entity4018 ). The impact of this mutation on disease phenotype in @entity4407 and @entity4018 is still a matter of discussion. This study aims to determine whether there are differences in clinical presentation and disease outcome between @entity4407 and @entity4018 @entity1 with and without the JAK2V617F mutation. MATERIALS AND METHODS: In this single-center study, a total of 184 consecutive Philadelphia-negative chronic @entity5 , 107 cases of @entity4407 and 77 cases of @entity4018 , were genotyped for JAK2V617F mutation using the @entity4016 Ipsogen MutaScreen assay, which involves allele-specific polymerase chain reaction. RESULTS: @entity4407 @entity1 positive for JAK2V617F mutation had higher hemoglobin (Hb) and hematocrit (Hct) levels, lower platelet counts, and more prevalent @entity381 at diagnosis compared to @entity1 negative for the JAK2V617F mutation, but rates of major @entity715 events, arterial @entity715 , and @entity49 were comparable between the groups. At presentation, @entity4018 @entity1 with JAK2V617F mutation had significantly higher Hb and Hct levels and leukocyte counts than @entity1 without the mutation. Similar to the findings of @entity4407 @entity1 , @entity1031 rates were similar in @entity4018 @entity1 with and without theJAK2V617F mutation. For @entity4407 and @entity4018 @entity1 , no difference was observed in rates of death with respect to JAK2V617F mutational status. Moreover, leukemic transformation rate was not different in our @entity4018 @entity1 with and without @entity4016 V617F mutation. CONCLUSION: We conclude that JAK2V617F-mutated @entity4407 @entity1 express a @entity6582 vera-like phenotype and JAK2V617F mutation in @entity4018 @entity1 is associated with a more pronounced myeloproliferative phenotype.
